DarioHealth (DRIO) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
10 Apr, 2026Platform overview and market opportunity
AI-powered, multi-condition platform addresses cardiometabolic, behavioral, and musculoskeletal health, supporting up to 6+ conditions on a single digital platform.
Unified offering delivers personalized care, cost savings, and efficiency, with bundled pricing at $74 per engaged member per month.
Large serviceable addressable market estimated at over $250 billion, with rapid expansion enabled by platform architecture.
70% of new wins and pipeline opportunities are multi-condition, reflecting strong market demand.
Blue-chip client base includes 160+ clients and partnerships with major employers, health plans, and pharma.
Clinical outcomes and user engagement
Over 100 published peer-reviewed studies validate clinical outcomes, including significant reductions in blood pressure, A1C, pain, and mental health symptoms.
5x ROI delivered to payers, with $5,077 in medical cost savings per user and 23% fewer hospitalizations.
75% of member measurements are in range, and 91% logo retention year-over-year.
Average member retention rate after 12 months is 75%, with 2.4 solutions used per member.
App Store rating of 4.8/5 from ~25,000 reviews highlights strong user satisfaction.
Technology and product differentiation
Proprietary AI leverages 13B+ user data points for personalized care, workflow optimization, and predictive analytics.
DarioIQ platform delivers adaptive, immersive health journeys, real-time data visualization, and timely interventions.
Multi-modal support includes connected devices, AI-powered coaching, community, and clinical services.
GLP-1 utilization management program integrates digital and live coaching, therapy, and medication support.
Asset-light model enables seamless access to therapy and specialty care via partner networks.
Latest events from DarioHealth
- Gross margin rose to 62% and net loss improved 39% as ARR, cash, and commercial wins increased.DRIO
Q2 2026 - AI-driven multi-condition platform delivers clinical results, high retention, and rapid growth.DRIO
Corporate presentation - Q1 2026 revenue rose to $5.6M, costs fell, but liquidity concerns remain despite strong pipeline.DRIO
Q1 2026 - Multi-condition digital health platform delivers strong growth, clinical outcomes, and high retention.DRIO
Corporate presentation - Registering up to $100M in securities to support growth and innovation in digital health.DRIO
Registration filing - Record new business and margin gains set the stage for accelerated, ARR-driven growth by 2027.DRIO
Q4 2025 - Amendment updates auditor consent for shelf registration; no changes to prospectus content.DRIO
Registration Filing - Q3 revenue up 111% YoY, but cash shortfall and delisting risk threaten future viability.DRIO
Q3 2024 - B2B2C revenue surged 315% year-over-year, driving margin gains and a path to breakeven by 2025.DRIO
Q2 2024